Immuneering Corporation - Special CallCompany ParticipantsBenjamin Zeskind - Co-Founder, President, CEO & DirectorConference Call ...
New research from Indiana University School of Medicine scientists has revealed that a well-known cancer-fighting gene also ...
Oncolytics Biotech shares rose after the company said it will meet with the Food and Drug Administration in November about advancing its treatment for pancreatic cancer to a clinical trial. The stock ...
What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and ...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of cancer, with fewer than 10 percent of patients surviving five years after diagnosis. A researcher at the University of ...
Oncolytics Biotech announced an update on its proposed registration-directed clinical trial for first-line pancreatic cancer treatment, featuring a three-arm design to evaluate the efficacy of ...
9h
Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing ...
Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor (“CPI”) in the neoadjuvant ...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most dangerous and fast-growing types of cancer. It spreads quickly and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback